Registration number: 10456081

Juno Genetics Ltd

Contents

Balance Sheet	1
Notes to the Financial Statements	2 to 7

Juno Genetics Ltd

(Registration number: 10456081)
Balance Sheet as at 31 December 2025

	Note	2025 £	2024 £
Fixed assets
Intangible assets	5	149,908	166,350
Tangible assets	6	705,523	825,390
		855,431	991,740
Current assets
Stocks	7	36,725	124,715
Debtors	8	1,647,634	1,123,035
Cash at bank and in hand		778,382	329,076
		2,462,741	1,576,826
Creditors: Amounts falling due within one year	9	(4,821,590)	(5,335,202)
Net current liabilities		(2,358,849)	(3,758,376)
Net liabilities		(1,503,418)	(2,766,636)
Capital and reserves
Called up share capital	10	100	100
Retained earnings		(1,503,518)	(2,766,736)
Shareholders' deficit		(1,503,418)	(2,766,636)

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 8 May 2026 and signed on its behalf by:
 

......................................... D Wells Director

Juno Genetics Ltd

Notes to the Financial Statements for the Year Ended 31 December 2025

1	General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
The Hayakawa Building
Oxford Science Park
Edmund Halley Road
Oxford
OX4 4GB

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis as the company's parent undertaking has confirmed that they will continue to support the company for the forseeable future.

Audit Report
The Independent Auditor's Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 8 May 2026 was Ajay Bahl BA BFP FCA, who signed for and on behalf of Wenn Townsend.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Juno Genetics Ltd

Notes to the Financial Statements for the Year Ended 31 December 2025

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Deferred Tax

The tax expense for the period comprises deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

The extent to which deferred tax assets can be recognised is based on an assessment of the profitability that future taxable income will be available against which the deductible temporary differences and tax loss carry-forwards can be utilised. In addition, significant judgement is required in assessing the impact of any legal or economic limits or uncertainties in various tax jurisdictions.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Office equipment	10-33% straight line
Leasehold property	10% straight line
Plant and machinery	12-15% straight line

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class	Amortisation method and rate
Internally generated software development costs	33% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Juno Genetics Ltd

Notes to the Financial Statements for the Year Ended 31 December 2025

Trade debtors

Trade debtors are amounts due from customers for services performed in the ordinary course of business.

Trade debtors are recognised at the transaction price.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing stock to its present location and condition. Cost is calculated using the first-in, first-out formula. Provision is made for damaged, obsolete and slow-moving stock where appropriate.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3	Staff numbers

The average number of persons employed by the company (including directors) during the year, was 15 (2024 - 15).

4	Profit/loss before tax

Arrived at after charging/(crediting)

	2025 £	2024 £
Depreciation expense	277,832	308,509
Amortisation expense	105,956	93,161

Juno Genetics Ltd

Notes to the Financial Statements for the Year Ended 31 December 2025

5	Intangible assets

	Internally generated software development costs £	Total £
Cost or valuation
At 1 January 2025	530,378	530,378
Additions acquired separately	89,514	89,514
At 31 December 2025	619,892	619,892
Amortisation
At 1 January 2025	364,028	364,028
Amortisation charge	105,956	105,956
At 31 December 2025	469,984	469,984
Carrying amount
At 31 December 2025	149,908	149,908
At 31 December 2024	166,350	166,350

6	Tangible assets

	Leasehold improvements £	Furniture, fittings and equipment  £	Total £
Cost or valuation
At 1 January 2025	1,041,779	1,411,014	2,452,793
Additions	-	192,528	192,528
Disposals	(104)	(197,364)	(197,468)
At 31 December 2025	1,041,675	1,406,178	2,447,853
Depreciation
At 1 January 2025	527,381	1,100,022	1,627,403
Charge for the year	104,168	173,664	277,832
Eliminated on disposal	-	(162,905)	(162,905)
At 31 December 2025	631,549	1,110,781	1,742,330
Carrying amount
At 31 December 2025	410,126	295,397	705,523
At 31 December 2024	514,398	310,992	825,390

Juno Genetics Ltd

Notes to the Financial Statements for the Year Ended 31 December 2025

Included within the net book value of land and buildings above is £410,126 (2024 - £514,398) in respect of long leasehold land and buildings.
 

7

Stocks

	2025 £	2024 £
Raw materials and consumables	36,725	124,715

8

Debtors

	Note	2025 £	2024 £
Trade debtors		729,746	473,481
Amounts owed by group undertakings and undertakings in which the company has a participating interest	12	363,079	334,160
Prepayments		108,621	128,868
Other debtors		446,188	186,526
		1,647,634	1,123,035

Included within other debtors is a deferred tax asset of £429,200 (2024: £171,080). There are losses totalling £1,892,556 (2024: £2,972,199) of unused tax losses for which the company has recognised a deferred tax asset in the balance sheet.

9

Creditors

Creditors: amounts falling due within one year

	Note	2025 £	2024 £
Due within one year
Trade creditors		81,921	59,999
Amounts owed to group undertakings and undertakings in which the company has a participating interest	12	4,546,870	5,125,228
Taxation and social security		65,762	57,922
Accruals and deferred income		127,037	92,053
		4,821,590	5,335,202

Juno Genetics Ltd

Notes to the Financial Statements for the Year Ended 31 December 2025

10	Share capital

Allotted, called up and fully paid shares

	2025		2024
	No.	£	No.	£
Ordinary shares of £0.001 each	100,000	100	100,000	100

11	Financial commitments, guarantees and contingencies

Amounts not provided for in the balance sheet

The total amount of financial commitments not included in the balance sheet is £Nil (2024 - £50,030). These relate to future minimum lease payments under non-cancellable operating leases.

12	Related party transactions

Summary of transactions with parent

Dagan Wells (Director) owns 5.5% of the share capital of the company, with the remaining 94.5% being held by RMA Global, S.L.U. (previously Equipo IVI). Dagan Wells received direcors remuneration at a market rate.

During the period the company repaid its parent undertaking RMA Global, S.L.U. (previously Equipo IVI) £574,628 (2024: £nil). The loan is interest free and repayable on demand. The total balance due to RMA Global, S.L.U. (previously Equipo IVI) at the balance sheet date is £4,471,985 (2024: £5,046,613).

The company owed £74,885 (2024:£78,615) and was owed £363,079 (2024:£334,160) to other group companies. All transactions were on normal commercial terms.

13	Parent and ultimate parent undertaking

The company's immediate parent is IVI RMA Global S.L.(Previously Equipo IVI), incorporated in Spain.

 The ultimate parent is Inception Topco S.a.r.l, incorporated in Luxembourg.

 The most senior parent entity producing publicly available financial statements is Inception Topco S.a.r.l. These financial statements are available upon request from 2 Rue Edward Steichen, L-2540 Luxembourg